Published in Br J Cancer on February 17, 2009
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood (2012) 2.35
Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in vivo and impairs their ability to form tumor spheres. Mol Cancer (2010) 1.50
The Critical Impact of HIF-1a on Gastric Cancer Biology. Cancers (Basel) (2013) 1.08
Annexin A1, A2, A4 and A5 play important roles in breast cancer, pancreatic cancer and laryngeal carcinoma, alone and/or synergistically. Oncol Lett (2012) 1.01
Targeting mTOR pathway: A new concept in cancer therapy. Indian J Med Paediatr Oncol (2010) 0.99
Expression of monocyte chemotactic protein-1/CCL2 in gastric cancer and its relationship with tumor hypoxia. World J Gastroenterol (2014) 0.92
The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo. BMC Med (2010) 0.92
Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma. Histochem Cell Biol (2009) 0.89
Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents. J Med Chem (2012) 0.89
Glyoxalase-I is a novel prognosis factor associated with gastric cancer progression. PLoS One (2012) 0.84
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl) (2015) 0.84
Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J Gastroenterol (2014) 0.83
Dual inhibition of plasminogen kringle 5 on angiogenesis and chemotaxis suppresses tumor metastasis by targeting HIF-1α pathway. PLoS One (2012) 0.81
Peritoneal milky spots serve as a hypoxic niche and favor gastric cancer stem/progenitor cell peritoneal dissemination through hypoxia-inducible factor 1α. Stem Cells (2014) 0.79
Heterogenous ribonucleoprotein A18 (hnRNP A18) promotes tumor growth by increasing protein translation of selected transcripts in cancer cells. Oncotarget (2016) 0.79
Lentivirus-mediated RASSF1A expression suppresses aggressive phenotypes of gastric cancer cells in vitro and in vivo. Gene Ther (2015) 0.78
Annexin A1 sustains tumor metabolism and cellular proliferation upon stable loss of HIF1A. Oncotarget (2016) 0.76
Hypoxia regulates CD44 expression via hypoxia-inducible factor-1α in human gastric cancer cells. Oncol Lett (2016) 0.75
Bile acids destabilise HIF-1α and promote anti-tumour phenotypes in cancer cell models. BMC Cancer (2016) 0.75
Modulation of urokinase plasminogen activator system by poly(ADP-ribose)polymerase-1 inhibition. Cytotechnology (2014) 0.75
Molecular-targeted therapy hypoxia in head and neck squamous cell carcinoma patients. Mol Clin Oncol (2012) 0.75
Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes. Am J Cancer Res (2017) 0.75
Targeting HIF-1 for cancer therapy. Nat Rev Cancer (2003) 28.01
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer (2002) 20.51
Global cancer statistics in the year 2000. Lancet Oncol (2001) 11.11
Tumor metastasis: mechanistic insights and clinical challenges. Nat Med (2006) 11.06
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 10.65
HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell (2003) 9.12
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev (2000) 5.16
HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med (2002) 4.13
Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol (2001) 4.03
Gastric cancer. Lancet (2003) 3.96
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell (2003) 3.66
Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (2003) 3.47
Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res (2000) 3.35
V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res (1997) 3.17
Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res (2007) 3.01
Predominant role of hypoxia-inducible transcription factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res (2003) 2.93
A versatile tool for conditional gene expression and knockdown. Nat Methods (2006) 2.92
YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst (2003) 2.91
Axis of evil: molecular mechanisms of cancer metastasis. Oncogene (2003) 2.81
Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res (2001) 2.14
Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Lab Invest (2006) 2.14
Tumor hypoxia and malignant progression. Methods Enzymol (2004) 2.06
Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res (2006) 1.89
Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst (2004) 1.82
Hypoxia-inducible factor-1-independent regulation of vascular endothelial growth factor by hypoxia in colon cancer. Cancer Res (2004) 1.76
Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. Cancer Res (2006) 1.66
Expression of hypoxia-inducible factor-1alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer (2003) 1.60
Comparison of three retroviral vector systems for transduction of nonobese diabetic/severe combined immunodeficiency mice repopulating human CD34+ cord blood cells. Hum Gene Ther (2003) 1.58
Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res (1998) 1.47
HIF-1 and hypoxic response: the plot thickens. Curr Opin Genet Dev (2004) 1.34
Overexpression of hypoxia-inducible-factor 1alpha(HIF-1alpha) in oesophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Br J Cancer (2003) 1.24
Hypoxia-inducible factor-1alpha expression and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncol Rep (2003) 1.21
Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis (2004) 1.20
Clinicopathologic significance of hypoxia-inducible factor 1alpha overexpression in gastric carcinomas. J Surg Oncol (2006) 1.15
Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer (2006) 1.15
Hypoxia and HIF-1alpha in osteoarthritis. Int Orthop (2004) 1.13
Hypoxia-inducible factor-1alpha is associated with risk of aggressive behavior and tumor angiogenesis in gastrointestinal stromal tumor. Jpn J Clin Oncol (2005) 1.13
Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. J Biomed Sci (2005) 1.12
Regulation of the chemokine receptor CXCR4 and metastasis by hypoxia-inducible factor in non small cell lung cancer cell lines. Cancer Biol Ther (2006) 1.04
Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1alpha-independent manner. Int J Oncol (2006) 0.98
Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer (2006) 0.95
Gastrin transactivates the chromogranin A gene through MEK-1/ERK- and PKC-dependent phosphorylation of Sp1 and CREB. Cell Signal (2007) 0.92
Phenanthroquinolizidine alkaloids from the roots of Boehmeria pannosa potently inhibit hypoxia-inducible factor-1 in AGS human gastric cancer cells. J Nat Prod (2006) 0.91
[2-Methoxyestradiol -- a new compound for cancer treatment]. Dtsch Med Wochenschr (2006) 0.77
Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol (2001) 11.41
Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell (1985) 6.06
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch (2006) 5.86
Hyperthermia in combined treatment of cancer. Lancet Oncol (2002) 4.41
TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch (2007) 3.89
Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res (2001) 3.23
Transport route for synaptobrevin via a novel pathway of insertion into the endoplasmic reticulum membrane. EMBO J (1995) 2.96
Clathrin-coated vesicles contain an ATP-dependent proton pump. Proc Natl Acad Sci U S A (1983) 2.84
Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology (2000) 2.66
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol (2004) 2.54
Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology (2005) 2.49
Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology (1993) 2.29
Palliative endoscopic therapy of rectal carcinoma. Eur J Cancer (1996) 2.22
Miniprobe confocal laser microscopy for the detection of invisible neoplasia in patients with Barrett's oesophagus. Gut (2008) 2.20
Frequency-domain techniques enhance optical mammography: initial clinical results. Proc Natl Acad Sci U S A (1997) 2.15
Probe-based confocal laser endomicroscopy compared with standard four-quadrant biopsy for evaluation of neoplasia in Barrett's esophagus. Endoscopy (2010) 2.11
Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol (2000) 2.03
Curative endoscopic therapy in patients with early esophageal squamous-cell carcinoma or high-grade intraepithelial neoplasia. Endoscopy (2007) 1.94
Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc (2000) 1.94
Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiative. Aliment Pharmacol Ther (2003) 1.91
Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res (2000) 1.90
Magnetic resonance cholangiopancreatography-guided unilateral endoscopic stent placement for Klatskin tumors. Gastrointest Endosc (2001) 1.90
In vivo diagnosis of collagenous colitis by confocal endomicroscopy. Gut (2006) 1.82
Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study. Aliment Pharmacol Ther (2011) 1.76
Assessment of the size, position, and optical properties of breast tumors in vivo by noninvasive optical methods. Appl Opt (1998) 1.76
Treatment of oesophageal anastomotic leaks by temporary stenting with self-expanding plastic stents. Br J Surg (2009) 1.74
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
Molecular characterization of synaptophysin, a major calcium-binding protein of the synaptic vesicle membrane. EMBO J (1986) 1.73
LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut (2001) 1.72
Pancreatic carcinoma. Lancet (1997) 1.72
Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis. Br J Surg (2006) 1.71
Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci U S A (1986) 1.70
TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst (2012) 1.65
OLGA staging for gastritis: a tutorial. Dig Liver Dis (2008) 1.64
Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity. Dig Dis (2001) 1.63
Suppression of tumorigenicity in breast cancer cells by the microfilament protein profilin 1. J Exp Med (2000) 1.61
Strong indication for a breast cancer susceptibility gene on chromosome 8p12-p22: linkage analysis in German breast cancer families. Oncogene (1997) 1.61
Health-related quality of life in patients with pancreatic cancer. Digestion (2006) 1.57
Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD study. Dig Liver Dis (2006) 1.57
Comparison of quality of life in patients undergoing abdominoperineal extirpation or anterior resection for rectal cancer. Ann Surg (2001) 1.55
European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis (2013) 1.53
Comparison of methylene blue-directed biopsies and four-quadrant biopsies in the detection of high-grade intraepithelial neoplasia and early cancer in Barrett's oesophagus. Dig Liver Dis (2006) 1.53
[S3-Guidelines "Exocrine pancreatic cancer" 2007]. Z Gastroenterol (2007) 1.52
Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol (1987) 1.51
The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model. Gut (2008) 1.49
Valid symptom reporting at upper endoscopy in a random sample of the Swedish adult general population: the Kalixanda study. Scand J Gastroenterol (2004) 1.49
Reverse mosaicism in Fanconi anemia: natural gene therapy via molecular self-correction. Cytogenet Genome Res (2002) 1.49
Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol (2004) 1.47
Management and outcomes of haemorrhage after pancreatogastrostomy versus pancreatojejunostomy. Br J Surg (2011) 1.46
Increased autologous blood donation in rectal cancer by recombinant human erythropoietin (rhEPO) Eur J Cancer (1998) 1.45
European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy (2012) 1.44
[Lymphatic mapping and sentinel lymph node biopsy in gastric cancer]. Chirurg (2003) 1.44
Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol (2001) 1.43
[Atypical celiac disease in a patient with type 1 diabetes mellitus and Hashimoto's thyreoiditis]. Dtsch Med Wochenschr (2011) 1.43
Three-dimensional endoluminal ultrasound: a new method for the evaluation of gastrointestinal tumors. Abdom Imaging (1999) 1.42
Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther (2003) 1.40
Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol (1993) 1.39
[The status of diagnosis of Barrett esophagus. An analysis of 1000 histologically diagnosed cases]. Dtsch Med Wochenschr (1997) 1.39
[Remove polyps and discard. Way or wrong way?]. Pathologe (2015) 1.39
The location of small tumor deposits in the SLN predicts Non-SLN macrometastases in breast cancer patients. Eur J Surg Oncol (2007) 1.39
Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun (2006) 1.38
Vascular endothelial growth factor in articular cartilage of healthy and osteoarthritic human knee joints. Ann Rheum Dis (2001) 1.38
De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology (2000) 1.37
Confocal laser endomicroscopy: technical status and current indications. Endoscopy (2006) 1.36
Topogenesis and sorting of synaptophysin: synthesis of a synaptic vesicle protein from a gene transfected into nonneuroendocrine cells. Cell (1989) 1.32
Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut (2001) 1.32
Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL. Am J Physiol Renal Physiol (2007) 1.28
Analysis of symptoms and endoscopic findings in 117 patients with histological diagnoses of eosinophilic esophagitis. Endoscopy (2007) 1.27
Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut (2005) 1.27
A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor. J Cell Biol (2000) 1.26
Development of a time-domain optical mammograph and first in vivo applications. Appl Opt (1999) 1.25
Differentiation of pluripotent embryonic stem cells into the neuronal lineage in vitro gives rise to mature inhibitory and excitatory neurons. Mech Dev (1995) 1.24
Evaluation of endocytoscopy in the surveillance of patients with Barrett's esophagus. Endoscopy (2007) 1.24
Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. Hepatology (2000) 1.23
Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. Gut (2007) 1.22
Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut (1996) 1.22
Regulatory peptide receptors in human hepatocellular carcinomas. Gut (1999) 1.22
Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett's esophagus (SSBE): curative treatment using local endoscopic treatment techniques. Endoscopy (2002) 1.20
In-vivo confocal real-time mini-microscopy in animal models of human inflammatory and neoplastic diseases. Endoscopy (2007) 1.17
Specific detection and prevalence of Helicobacter heilmannii-like organisms in the human gastric mucosa by fluorescent in situ hybridization and partial 16S ribosomal DNA sequencing. J Clin Microbiol (2001) 1.15
A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer. Oncogene (1996) 1.12
Hyperthermia-induced nuclear translocation of transcription factor YB-1 leads to enhanced expression of multidrug resistance-related ABC transporters. J Biol Chem (2001) 1.12
Mechanisms of diarrhea in the interleukin-2-deficient mouse model of colonic inflammation. Am J Physiol Gastrointest Liver Physiol (2004) 1.12
Overexpression of sialyltransferase CMP-sialic acid:Galbeta1,3GalNAc-R alpha6-Sialyltransferase is related to poor patient survival in human colorectal carcinomas. Cancer Res (2001) 1.11